



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

10

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/003,810	01/07/98	RAMAKRISHNAN	V 44481-5017-0

009629
MORGAN, LEWIS & BOCKIUS
1800 M STREET NW
WASHINGTON DC 20036-5869

HM12/0817

EXAMINER

GAMBEL, P

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED:

21
08/17/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

09/003810

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
1644	20

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

In re Application of
RAMAKRISHNAN ET AL.
Serial No. 09/003,810
Filed: January 7, 1998
For: METHODS OF TREATING PDGF-MEDIATED DISEASES WITH BETA-PDGF RECEPTOR
IMMUNOGLOBULIN POLYPEPTIDES

SUSPENSION OF PROSECUTION

All claims are allowable. However due to a potential interference, ex parte prosecution is
SUSPENDED pending a determination as to whether an interference proceeding is appropriate.

In view of applicant's Petition to Correct Inventorship Under 37 CAR 1.48(b), filed 6/2/98; the
inventorship in this nonprovisional application has been changed by the deletion of Lokker.

The inventors of the claimed invention are Ramakrishnan, Escobedo and Fretto.

Applicant's submission, filed 9/27/99 (Paper No. 7), has placed the instant application in compliance
with the Sequence Rules.

It is apparent that the 2A1E2 antibody is required to practice the claimed invention (claim 38). As a
required element, it must be known and readily available to the public or obtainable by a repeatable
method set forth in the specification. If it is not so obtainable or available, the enablement requirements
of 35 USC 112, first paragraph, may be satisfied by a deposit of the appropriate cell line / hybridoma
which produces this antibody. See 37 CAR 1.801-1.809.

Given the patented claims set forth in U.S. Patent 5,817,310, the deposit requirements for the 2A1E2
antibody produced by the hybridoma ATCC NO. 10938 have been satisfied.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel
whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am
to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are
unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or
relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number
is (703) 308-0196.

Phillip Gambel, PhD.

Primary Examiner

Technology Center 1600

August 14, 2000

Phillip Gambel